Trinity Biotech PLC

191 articles about Trinity Biotech PLC

• Trinity Biotech Announces CLIA Waiver Of Rapid Syphilis Test

  12/17/2014

• Trinity Biotech Temporary Suspends Meritas Troponin Trials

  10/23/2014

• Trinity Biotech To Announce Third Quarter Fiscal 2014 Financial Results

  10/6/2014

• Trinity Biotech Announces CE Marking of New Meritas Heart Failure (BNP) Point-of-Care Test

  9/25/2014

• Trinity Biotech Announces Quarter 2 Financial Results; 25 Percent Increase In Operating Profits

  7/29/2014

• Trinity Biotech Announces Quarter 1 Results

  4/29/2014

• Trinity Biotech To Announce First Quarter Fiscal Year 2014 Financial Results

  4/16/2014

• Trinity Biotech Announces Results For Q4 And Fiscal Year 2013

  3/4/2014

• Trinity Biotech To Announce Fourth Quarter And Fiscal Year 2013 Financial Results

  2/19/2014

• Trinity Biotech Announces European Approval Of Guideline Compliant, Point-Of-Care, High Sensitivity Troponin I Product

  1/29/2014

• Trinity Biotech Announces Quarter 3 Financial Results, Acquisition of Blood Bank Screening Business and FDA Approval of HIV-2 Claim

  10/17/2013

• Trinity Biotech to Announce Third Quarter Fiscal Year 2013 Financial Results

  9/30/2013

• Trinity Biotech Buys IMMCO Diagnostics for $32.75 Million, Reports Earnings

  7/30/2013

• Trinity Biotech to Announce Second Quarter Fiscal Year 2013 Financial Results

  7/23/2013

• Trinity Biotech Announces Quarter 3 Financial Results

  10/18/2012

• Trinity Biotech to Announce Third Quarter Fiscal Year 2012 Financial Results

  10/4/2012

• Trinity Biotech Announces Quarter 2 Financial Results EPS of 20 Cents Per ADR -- an Increase of 11%

  7/12/2012

• Trinity Biotech to Announce Second Quarter Fiscal Year 2012 Financial Results

  7/5/2012

• Trinity Biotech Announces Details of Its Dividend and Share Buyback Program

  6/6/2012

• Trinity Biotech Announces an Annual Dividend of 15 Cents Per ADR -- an Increase of 50%

  4/25/2012